Parexel rejigs its randomization tech with an eye on speed

CRO giant Parexel ($PRXL) has updated its technology for patient randomization and clinical supply management, touting the latest version as a valuable tool for speeding up the process of designing studies. The platform, called ClinPhone RTSM, is designed to simplify study startup. And, integrating new technologies from recent acquisition ClinIntel, Parexel believes the new, fourth-generation software can further save sponsors time and money. More

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.